{
    "root": "056ed002-5bed-49d6-a075-e2aa274e008e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "DANYELZA",
    "value": "20250520",
    "ingredients": [
        {
            "name": "Naxitamab",
            "code": "9K8GNJ2874",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15965"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "Water",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "danyelza indicated , combination granulocyte-macrophage colony-stimulating factor ( gm-csf ) , treatment pediatric patients 1 year age older adult patients relapsed refractory high-risk neuroblastoma bone bone marrow demonstrated partial response , minor response , stable disease prior therapy . indication approved accelerated approval based overall response rate duration response [ ( 14 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) .",
        "doid_entities": [
            {
                "text": "neuroblastoma (DOID:769)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_769"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended danyelza 3 mg/kg/day ( 150 mg/day ) , administered intravenous infusion dilution days 1 , 3 , 5 treatment cycle . treatment cycles repeated every 4 weeks complete response partial response , followed 5 additional cycles every 4 weeks . subsequent cycles may repeated every 8 weeks . discontinue danyelza gm-csf disease progression unacceptable toxicity . administer gm-csf subcutaneously prior treatment cycle recommended . ( 2.1 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "gm-csf disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_190"
            }
        ]
    },
    "warningsAndPrecautions": "danyelza ( naxitamab-gqgk ) injection sterile , preservative-free , clear slightly opalescent colorless slightly yellow solution intravenous infusion supplied carton containing one 40mg/10 ml ( 4 mg/ml ) single-dose vial . ndc 73042-201-01",
    "adverseReactions": "danyelza contraindicated patients history severe hypersensitivity reaction naxitamab-gqgk . included anaphylaxis [ ( 5.1 ) ] .",
    "indications_original": "DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n                  This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contraindications_original": "The recommended dosage of DANYELZA is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on Days 1, 3, and 5 of each treatment cycle. Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks.  Subsequent cycles may be repeated every 8 weeks.  Discontinue DANYELZA and GM-CSF for disease progression or unacceptable toxicity. Administer GM-CSF subcutaneously prior to and during each treatment cycle as recommended.  ( 2.1 )",
    "warningsAndPrecautions_original": "DANYELZA (naxitamab-gqgk) injection is a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellow solution for intravenous infusion supplied as a carton containing one 40mg/10 mL (4 mg/mL) single-dose vial.\n                  NDC 73042-201-01",
    "adverseReactions_original": "DANYELZA is contraindicated in patients with a history of severe hypersensitivity reaction to naxitamab-gqgk. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)].",
    "drug": [
        {
            "name": "DANYELZA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15965"
        }
    ]
}